Leap Therapeutics Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with DKN-01 in Esophagogastric Cancer
June 21, 2017 09:07 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., June 21, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that it has...
Leap Therapeutics to Present at Two Investor Conferences in June
June 01, 2017 07:00 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
May 17, 2017 17:16 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported interim data...
Leap Therapeutics Reports First Quarter 2017 Financial Results
May 12, 2017 07:00 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., May 12, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
Leap Therapeutics to Present DKN-01 Clinical Data at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
April 20, 2017 12:00 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that interim...
Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting
April 03, 2017 07:00 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported non-clinical and...
Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers
March 31, 2017 16:36 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
Leap Therapeutics to Present at Two Investor Conferences in April
March 29, 2017 07:00 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
Leap Therapeutics to Present at 2017 Barclays Global Healthcare Conference
March 07, 2017 07:00 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
Leap Therapeutics to Present Preclinical and Clinical Data at 2017 AACR Annual Meeting
March 01, 2017 18:39 ET
|
Leap Therapeutics
CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced preclinical...